REGISTER RECORD · ctis
2023-503990-39-00
SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | The register records no status for this entry. |
|---|---|
| Register last updated | 2026-09-08 |
| Retrieved by this site | 2026-10-03 |
| Source | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-503990-39-00 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.